Hospital Acquired Infection Testing Market: By Product (Sterilant, Disinfectants, and Other Products), By Infection type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections, and Other Indications), By End User (Hospitals and Intensive Care Units, Ambulatory Surgical and Diagnostic Centres, Nursing Homes, and Maternity Centres), and By Geography

Hospital Acquired Infection Testing Market was valued at USD 3,482.1 million in 2022 and is expected to grow at 7.6% CAGR during the forecast period. Hospital-acquired infection (HAI), also called nosocomial infection is caused by bacterial, fungal, and viral pathogens while receiving treatment in healthcare facilities. The high prevalence of these HAIs is expected to significantly drive the demand for its therapeutics and fuel market growth in the coming years. According to the report published by the Organisation for Economic Co-operation and Development (OECD) in 2018, annually around 3.8 million people in EU countries acquire a healthcare-associated infection in acute care hospitals. The same source also states that each year around 90,000 people in the EU countries die due to some type of HAIs. The high prevalence of HAI and increasing resistance to available antibiotics have significantly fuelled the demand for novel HAI therapeutics. Thus, major players in the market are involved in excessive R&D activities for the development of new HAI drugs and gaining their approval in major markets. For instance, in June 2019, the FDA approved an expanded indication of Merck & Co., Inc.’s drug Zerbaxa (ceftolozane and tazobactam), for the treatment of ventilator-associated bacterial pneumonia (HABP/VABP) and hospital-acquired bacterial pneumonia in patients 18 years and older. In recent decades, chronic diseases such as cancer, heart disease, diabetes, and arthritis have become major health issues with a rising prevalence globally. According to the data published by International Agency for Research on Cancer (IARC), the total number of new cancer cases was estimated to be around 18.1 million in 2018. The high prevalence of these chronic diseases has led to an increase in hospital admissions. For instance, according to the data published by the New York State Department of Health in November 2019, around 40% of adults in New York suffer from some type of chronic disease, which leads to around 23% of all hospitalizations. Thus, increasing hospitalizations due to the rising prevalence of chronic diseases is anticipated to result in higher cases of HAIs, aiding the growth of the market for HAIs therapeutics. In the recent past, there has been a significant decrease in the prevalence of HAIs in developing economies. Developed countries such as the USA, UK, and Germany are actively engaged in HAI preventive practices. Thus, the declining demand for HAI therapeutics in developed countries with increasing precautionary measures is anticipated to hinder the market growth.

Hospital-Acquired Infection Testing Market Key Developments:

• In November 2020, Sonoma Pharmaceuticals, Inc. and the MicroSafe Group DMCC reported that the COVID-19 list of disinfectants, kept by the United States Environmental Protection Agency's List N, now includes Nanocyn hospital-grade disinfectant.
• In November 2020, Innovative disinfectants Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray were introduced by PDI in March 2022 to aid infection prevention specialists in the ongoing fight against COVID-19 and the rising number of hospital-acquired infections (HAIs).